Screener
ADMA Biologics ADMA Paid-in-kind interest capitalized
Paid-in-kind interest capitalized at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:PaidInKindInterest.
The source filing: ADMA Biologics’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 5:16 PM EST
- Fiscal year
- FY2025
- Accession
- 0001140361-26-006815
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Depreciation and amortization | 8,096 | 8,045 | 8,332 |
| Loss on disposal of fixed assets | 9 | 106 | 182 |
| Deferred income tax provision | 11,020 | (84,280) | - |
| Interest paid in kind | - | - | 3,836 |
| Stock-based compensation | 20,026 | 13,616 | 6,187 |
| Amortization of debt discount | 717 | 951 | 2,594 |
| Loss on extinguishment of debt | 3,336 | 1,243 | 26,174 |
| Amortization of license revenue | (143) | (143) | (143) |
Item 16.
FAQ
- What is ADMA Biologics's paid-in-kind interest capitalized?
- ADMA Biologics (ADMA) reported paid-in-kind interest capitalized of $0 in Q4 2025.
- What is the long-term trend for ADMA Biologics's paid-in-kind interest capitalized?
- Over 2 years (2023 to 2025), ADMA Biologics's paid-in-kind interest capitalized has grown at a -100.0% compound annual growth rate (CAGR), from $3.84M to $0.
- What does paid-in-kind interest capitalized mean?
- This metric tracks interest expense that is settled by increasing the principal amount of a debt obligation rather than through cash payments. It is a critical indicator of debt structure and the company's reliance on non-cash financing to manage interest burdens.
Ask your AI about ADMA Biologics's paid-in-kind interest capitalized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude